InspireMD (NSPR) Peer Comparison

$0.85

$-0.04 (-4.35%)

As on 28-Aug-2026 16:00EDT

Market cap

$40 Mln

Revenue (TTM)

$11 Mln

P/E Ratio

--

P/B Ratio

1.3

Div. Yield

0 %

Edit

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	40	12,753	10,906	9,948	9,762
Revenue ($ Mln)	11	1,505	613	785	2,589
Net Profit ($ Mln)	-38.50	160.59	-188.05	41.54	222.40
Net Margin (%)	-355.17	10.67	-30.68	5.29	8.59
RoE (%)	-88.81	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	1.32	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	10.84	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	8.88	483.98	127.96	384.30	1,245.50
Gross Profit	2.65	942.44	393.22	347.62	1,343.60
Operating Expenses	55.52	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-53.56	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-38.44	203.83	-192.83	52.15	350.40
Provision for Tax	0.06	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-38.50	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	31.51	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	3.48	210.18	135.71	705.49	2,116.80
Current Liabilities	9.65	233.78	102.33	132.66	961.30
Total Liabilities	69.40	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	8.01	630.60	404.74	1,749.63	7,231.50
Current Assets	36.63	1,344.12	515.78	1,200.55	3,020.50
Total Assets	69.40	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	1.97	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-35.10	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-30.56	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	55.57	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-100.68	11.76	-22.53	1.79	8.98
ROE (%)	-88.81	10.86	-28.10	1.97	3.04
ROA (%)	-62.26	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-354.59	13.63	-30.58	9.87	-5.99
Net Margin (%)	-355.17	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	53.42	17.55	41.55	16.49	1.37
EBIT Growth (%)	6.67	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	6.95	8.72	-102.66	400.42	-30.32
EPS Growth (%)	37.00	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	8.07	17.33	-12.65	2.16	2.19

Valuation Ratios

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-2.68	68.93	-34.59	189.42	--
Price / Book Value	1.32	8.58	9.90	4.86	--
Dividend Yield (%)	0.00	--	--	0.00	--
EV/EBITDA	0.29	53.25	-43.50	81.02	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.00	0.01	0.00	0.01	0.06
Current Ratio	3.80	5.75	5.04	9.05	3.14
Quick Ratio	3.52	3.86	4.46	7.64	2.33
Interest Coverage	--	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	InspireMD (NSPR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	22.21	12.65	22.67	20.09	17.06
Asset Turnover	0.18	0.74	0.59	0.26	0.24
Receivable days	98.08	46.54	60.95	72.41	65.39
Inventory Days	172.12	331.92	193.84	146.53	221.09
Payable days	72.39	26.16	60.19	29.05	37.02
Cash Conversion Cycle	197.81	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly